227 related articles for article (PubMed ID: 15934103)
21. Prevalence of valvular involvement in systemic lupus erythematosus and association with antiphospholipid syndrome: a matched echocardiographic study.
Metz D; Jolly D; Graciet-Richard J; Nazeyrollas P; Chabert JP; Maillier B; Pennaforte JL; Elaerts J
Cardiology; 1994; 85(2):129-36. PubMed ID: 7954564
[TBL] [Abstract][Full Text] [Related]
22. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus.
Plazak W; Gryga K; Milewski M; Podolec M; Kostkiewicz M; Podolec P; Musial J
Lupus; 2011 Aug; 20(9):936-44. PubMed ID: 21636627
[TBL] [Abstract][Full Text] [Related]
23. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?
Mok MY; Farewell VT; Isenberg DA
Ann Rheum Dis; 2000 Jun; 59(6):462-7. PubMed ID: 10834864
[TBL] [Abstract][Full Text] [Related]
25. Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease.
Bulckaen HG; Puisieux FL; Bulckaen ED; Di Pompeo C; Bouillanne OM; Watel AA; Fauchais AL; De Groote P; Millaire A
Mayo Clin Proc; 2003 Mar; 78(3):294-8. PubMed ID: 12630582
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis.
Wahl DG; Bounameaux H; de Moerloose P; Sarasin FP
Arch Intern Med; 2000 Jul; 160(13):2042-8. PubMed ID: 10888978
[TBL] [Abstract][Full Text] [Related]
27. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
Martinez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Garmendia M; Gabriel Erdozain J; Villar I; Aguirre C
Lupus; 2007; 16(10):810-6. PubMed ID: 17895304
[TBL] [Abstract][Full Text] [Related]
28. Assessment of echocardiographic abnormalities in patients with systemic lupus erythematosus: correlation with levels of antiphospholipid antibodies.
Gentile R; Laganà B; Tubani L; Casato M; Ferri GM; Fedele F
Ital Heart J; 2000 Jul; 1(7):487-92. PubMed ID: 10933332
[TBL] [Abstract][Full Text] [Related]
29. [Comparative analysis of clinical and laboratory charactiristics of antiphospholipid syndrome].
Soltész P; Veres K; Kiss E; Lakos G; Sonkoly I; Muszbek L; Szegedi G
Orv Hetil; 2000 Dec; 141(52):2821-5. PubMed ID: 11202118
[TBL] [Abstract][Full Text] [Related]
30. Valvular heart disease and systemic lupus erythematosus: therapeutic implications.
Fluture A; Chaudhari S; Frishman WH
Heart Dis; 2003; 5(5):349-53. PubMed ID: 14503933
[TBL] [Abstract][Full Text] [Related]
31. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
Somers E; Magder LS; Petri M
J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
[TBL] [Abstract][Full Text] [Related]
32. Epileptic seizures in systemic lupus erythematosus.
Appenzeller S; Cendes F; Costallat LT
Neurology; 2004 Nov; 63(10):1808-12. PubMed ID: 15557494
[TBL] [Abstract][Full Text] [Related]
33. Antiphospholipid antibody tests: spreading the net.
Bertolaccini ML; Gomez S; Pareja JF; Theodoridou A; Sanna G; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Nov; 64(11):1639-43. PubMed ID: 15817655
[TBL] [Abstract][Full Text] [Related]
34. [Cardiac anomalies in systemic lupus erythematosus: their prevalence and relation to duration, disease activity and the presence of antiphospholipid antibodies].
Lolli C; Foscoli M; Giofrè R; Tarquinii M; Pasquali S; Toschi GP
G Ital Cardiol; 1993 Nov; 23(11):1125-34. PubMed ID: 8163102
[TBL] [Abstract][Full Text] [Related]
35. Valvulitis requiring triple valve surgery as an initial presentation of systemic lupus erythematosus.
Einav E; Gitig A; Marinescu LM; Tanaka KE; Spevack DM
J Am Soc Echocardiogr; 2007 Nov; 20(11):1315.e1-3. PubMed ID: 17600680
[TBL] [Abstract][Full Text] [Related]
36. Lupus anticoagulants and antiphospholipid antibodies monitoring in systemic lupus erythematosus.
Ariano CC; Salmaggi A; Croci D; Lamperti E; Bottero P; Castiglione A; Venegoni E; La Mantia L; Eoli M
Contrib Nephrol; 1992; 99():118-22. PubMed ID: 1458916
[No Abstract] [Full Text] [Related]
37. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study.
Berube C; Mitchell L; Silverman E; David M; Saint Cyr C; Laxer R; Adams M; Vegh P; Andrew M
Pediatr Res; 1998 Sep; 44(3):351-6. PubMed ID: 9727712
[TBL] [Abstract][Full Text] [Related]
38. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.
Neville C; Rauch J; Kassis J; Chang ER; Joseph L; Le Comte M; Fortin PR
Thromb Haemost; 2003 Jul; 90(1):108-15. PubMed ID: 12876633
[TBL] [Abstract][Full Text] [Related]
39. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus.
Khamashta MA; Cervera R; Asherson RA; Font J; Gil A; Coltart DJ; Vázquez JJ; Paré C; Ingelmo M; Oliver J
Lancet; 1990 Jun; 335(8705):1541-4. PubMed ID: 1972484
[TBL] [Abstract][Full Text] [Related]
40. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
Mustonen P; Lehtonen KV; Javela K; Puurunen M
Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
